T

Tata Medical Center | Tata Translational Cancer Research Center

Research site
(Unclaimed)
Location
14 MAR (E-W), New Town, Rajarhat, Kolkata, West Bengal, India

Site insights

Top conditions

Top treatments

Daratumumab
Lenalidomide
Amivantamab
Lazertinib
Ibrutinib
Teclistamab
Degarelix
Gemcitabine
ImbruvicaTM
Inavolisib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 26 total trials
Locations recently updated

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, p...

Enrolling
Relapsed Advanced Lymphomas
Drug: AUR108

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with ep...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Lazertinib
Drug: Amivantamab

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) a...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Carboplatin

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Amivantamab

The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.

Active, not recruiting
Lymphoma, Mantle-Cell
Drug: Bortezomib
Drug: Rituximab

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Carboplatin
Drug: LY3537982
Locations recently updated

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in comb...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Talquetamab

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcuta...

Enrolling
Metastatic Breast Cancer
Drug: Inavolisib
Drug: Optional Endocrine Therapy of Investigator's Choice

This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcita...

Active, not recruiting
Diffuse Large B-Cell Lymphoma
Drug: Oxaliplatin
Drug: Rituximab

The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in pati...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Darolutamide (Nubeqa, BAY1841788)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbocic...

Enrolling
Breast Cancer
Drug: Alpelisib
Drug: Fulvestrant

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control)...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Lenalidomide

Trial sponsors

J
Pfizer logo
Johnson & Johnson (J&J) logo
Roche logo
T
A
Bayer logo
C
Ferring logo
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems